RC48 plus gemcitabine before bladder cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old
- You must be planning to have bladder removal surgery
- Your cancer has spread into the bladder muscle but not to other organs (stage T2-T4aNxM0)
- Your tumor shows some level of HER2 protein (1+ to 3+ on a test)
- You have not had chemotherapy, immunotherapy, or HER2 treatment in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
This trial tests a new combination of two drugs before bladder removal surgery for patients with HER2-positive muscle-invasive bladder cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This study tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation therapy to treat bladder cancer while keeping the bladder intact. It aims to see if this approach can control the cancer without needing to remove the bladder.
Hear when a new MIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.